Follow on Google News News By Tag * Pharmaceutical * Drug * Healthcare * Generic * Ratings * Cagr * Medicines * Health * Devices * Expects * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | New Healthcare market report: "Australia Pharmaceuticals & Health"New Market Report Now Available: Australia Pharmaceuticals & Healthcare Report Q4 2010
However, the government has been attempting to slow inflation in healthcare spending by pressuring drug prices. In May 2010, the Australian government signed a four-year memorandum of understanding (MOU) with Medicines Australia, which represents drugmakers in the country. Under the terms of the agreement, Medicines Australia has agreed drug price cuts worth AUD2bn (US$1.76bn) for the government and AUD300mn (US$263.35mn) Meanwhile, BMI expects the popularity of generic drugs in Australia to increase following the publication of a study conducted by health economists from the University of Sydney. The research shows that the country could save nearly AUD10bn (US$9.1bn) over the next decade if the uptake of generic statins - which are used in the treatment of high cholesterol - is encouraged. Reforms to Australia's healthcare system, which BMI expects to succeed, will also accelerate the uptake of generic drugs following patent expiry of the originator product. Despite attempts by the pharmaceutical industry to temper the growth of the generics market, the latter is expected to record a local currency CAGR of 9.05% over 2009-2014. While BMI expects this growth rate to ease to 6.66% over 2009-2019, this expansion remains considerably higher than the 2.87% CAGR of the overall market in the same period. Although the government is prohibited from favouring the prescription of generics over the next four years under the Medicines Australia agreement, price reductions in generic drugs secured by the same agreement should help boost demand for these products. In May 2010, the government added AUD2.2bn (US$1.9bn) to healthcare spending over the next four years as part of the 2010-2011 federal budget. About AUD772mn (US$671.3mn) For more information or to purchase this report, go to: - http://www.fastmr.com/ Partial Table of Contents: Executive Summary SWOT Analysis - Australia Pharmaceuticals And Healthcare Industry SWOT - Australia Political SWOT - Australia Economic SWOT - Australia Business Environment SWOT Pharmaceutical Business Environment Ratings - Table: Asia Pacific - Regional Business Environment Ratings, Q410 - Rewards - Risks Australia - Market Summary Regulatory Regime - Table: Priorities Of the Therapeutic Goods Administrations Strategic Plan, 2006-2008 - OTC Switching Climate - Regional Regulatory Harmonisation - Recent Regulatory Developments - Intellectual Property Issues - Trade Agreements - Pricing and Reimbursement - Table: Historical PBS Co-payments - Price Cuts - Additions to Reimbursed Drugs List - Recent Pricing and Reimbursement Developments - Table New PBS Formularies - Table: Top Ten Prescription Drugs in Australia, 2007 Industry Trends and Developments - Epidemiology - Communicable Diseases - Mental Health Issues - E-Health - Prescribing Patterns - Private Healthcare Insurance - Biotechnology and Research - Recent Developments in the Biotechnology Sector - Clinical Trials - Recent Developments in the Clinical Trials Industry - Medical Devices - Table Examples Of Medical Devices Classifications - Recent Developments in the Medical Devices Sector Industry Forecast Scenario - Overall Market Forecast - Key Growth Factors - Industry - Key Growth Factors - Macroeconomic - Table: Australia - Economic Activity - Prescription Drug Market Forecast - Patented Drug Market Forecast - Generic Drug Market Forecast - OTC Medicine Market Forecast - Table: Pharmacy OTC Medicine Sales In Australia (US$), 2008 - Pharmaceutical Trade Forecast - Other Healthcare Data Forecasts - Key Risks to BMI's Forecast Scenario Competitive Landscape - Pharmaceutical Industry - Domestic Pharmaceutical Sector - Foreign Industry - Recent Company Developments - Retail Pharmacy Sector - Recent Developments in the Retail Pharmacy Sector Company Profiles - Indigenous Companies: - Sigma Pharmaceuticals - Australian Pharmaceutical Industries - Alphapharm (incorporated into Mylan) - Full Table of Contents is available at: -- http://www.fastmr.com/ About Business Monitor International Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports. View more research from Business Monitor International at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
| ||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number